Muscle Invasive Bladder Cancer Clinical Trial
Official title:
Radical Cystectomy Compared With Chemoradiation for Muscle Invasive Bladder Cancer: A Pilot, Randomized-Controlled Non-Inferiority Trial
Currently the standard treatment of muscle invasive bladder cancer is the complete removal of bladder and adjacent organs, such as prostate or ovaries. Radical cystectomy is fraught with complications and risk of death. The researchers hope to learn if chemoradiation (i.e. using chemotherapy and radiation), also an acceptable treatment for muscle invasive bladder cancer, can be used a good alternative therapy option.
Currently the standard treatment of muscle invasive bladder cancer is the complete removal of
bladder and adjacent organs, such as prostate or ovaries. Such procedure is highly invasive
and undesirable for some patients.
The researchers hope to learn if chemoradiation, using chemotherapy and radiation, can be a
good alternative therapy option. Chemoradiation therapy is also currently considered an
acceptable clinical approach but is typically used for treatment in patients with muscle
invasive bladder cancer who have other medical issues that might cause complications during
or after undergoing surgery. Disease free survival at 5 years is better for those who had
their bladder removed, but overall survival rates for chemoradiation therapy patients are
comparable between the two approaches.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04101812 -
Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT02546661 -
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT03732677 -
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
|
Phase 3 | |
| Recruiting |
NCT04047693 -
Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma
|
Phase 2 | |
| Recruiting |
NCT02648100 -
Basal Like Bladder Cancer : Signature and Therapeutic
|
N/A | |
| Terminated |
NCT03397394 -
Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05236218 -
To Better Understand the Most Important Factors for Patients When They Decide on the Type of Treatment They Receive for Muscle Invasive Bladder Cancer (MIBC).
|
||
| Active, not recruiting |
NCT04730219 -
Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma
|
Phase 2 | |
| Completed |
NCT03294304 -
BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy
|
Phase 2 | |
| Completed |
NCT03773666 -
A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)
|
Phase 1 | |
| Completed |
NCT01031420 -
Dose Dense MVAC for Muscle Invasive Bladder Cancer
|
Phase 2 | |
| Recruiting |
NCT04813107 -
A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03747419 -
Avelumab and Radiation in Muscle-Invasive Bladder Cancer
|
Phase 2 | |
| Recruiting |
NCT04960709 -
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
|
Phase 3 | |
| Not yet recruiting |
NCT05860543 -
Clinical Performance Evaluation of the C2i Test
|
||
| Recruiting |
NCT05979740 -
RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC
|
Phase 2 | |
| Active, not recruiting |
NCT04053101 -
Role of FDG-PET CT in the Management of Muscle Invasive Bladder Cancer
|